Mode
Text Size
Log in / Sign up

Lipid lowering therapy patterns in patients with ASCVD and familial hypercholesterolemia in IsraelLipid lowering therapy patterns observed in Israeli patients

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note the observed patterns of lipid lowering therapy and adherence in Israeli ASCVD and FH patients.

This retrospective database study investigated lipid lowering therapy (LLT) patterns in a population of treated patients with atherosclerotic cardiovascular disease (ASCVD), ASCVD-risk equivalent (ASCVD-RE), and familial hypercholesterolemia (FH). The study was conducted using data from Maccabi Healthcare Services in Israel.

The research focused on several secondary outcomes, including treatment patterns, adherence to lipid lowering therapy, low-density lipoprotein cholesterol (LDL-C) control, cardiovascular outcomes, and healthcare resource utilization. The study period spanned between 2013 and 2019.

Specific results regarding the primary outcome, treatment efficacy, or exact adherence rates were not reported in the provided data. No comparator group was specified for the evaluation of these therapy patterns.

Safety and tolerability data, including adverse events, serious adverse events, and discontinuation rates, were not reported. Limitations of the study were also not reported. Clinicians should note that this is an observational cohort study and results may not be generalizable to all populations.

This retrospective database study looked at patients in Israel who were treated for conditions like hypercholesterolemia, familial hypercholesterolemia, and atherosclerotic cardiovascular disease. The researchers examined data from Maccabi Healthcare Services between 2013 and 2019.

The study focused on how these patients used lipid lowering therapy. The researchers looked at various factors, including treatment patterns, how well patients stuck to their medication schedules, and how well they controlled their low density lipoprotein cholesterol (LDL-C). The study also looked at cardiovascular outcomes and how much healthcare resources were used.

Because this was a retrospective database study, it provides an overview of what happened in a specific group of people over several years. It does not provide new clinical trials or direct evidence of cause and effect. Readers should view these findings as a way to understand how treatment is currently being managed in this specific population.

What this means for you:
This study tracks how patients with high cholesterol and heart disease use lipid lowering therapy in Israel.

Study Details

Study typeCohort
EvidenceLevel 3
PublishedApr 2026
View Original Abstract ↓
AimsIn this retrospective study, we analyzed data from patients with hypercholesterolemia to describe treatment patterns, adherence, low-density lipoprotein cholesterol (LDL-C) control, cardiovascular outcomes, and healthcare resource utilization among treated patients in a real-world setting in Israel.MethodsDeidentified data from the medical records of patients with atherosclerotic cardiovascular disease (ASCVD), ASCVD-risk equivalent (ASCVD-RE), and familial hypercholesterolemia (FH) treated with lipid-lowering therapy (LLT) between 2013 and 2019 were analyzed. LDL-C values were based on routine laboratory reporting in Maccabi Healthcare Services and were calculated using the Friedewald equation during the study period. Controlled LDL-C was defined as LDL-C 
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.